Medical News

RSS

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced it has received European CE Mark approval of its Eon family of neurostimulators for patients with intractable chronic migraine. Unveiled at the European Headache and Migraine Trust International Congress in London, this approval includes the Eon Mini neurostimulator, which is the world's smallest rechargeable neurostimulator with the longest-lasting battery in its class, and the Eon and EonC neurostimulators.

21 Sep 2012

Newly formed emotional memories can be erased from the human brain

Newly formed emotional memories can be erased from the human brain. This is shown by researchers from Uppsala University in a new study now being published by the academic journal Science. The findings may represent a breakthrough in research on memory and fear.

21 Sep 2012

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration.

21 Sep 2012

Research to gauge effectiveness of street-crossing training program in impaired people

An Indiana University assistant professor and low-vision optometrist working to advance pedestrian safety has been awarded more than $1.9 million by the National Institutes of Health to evaluate street-crossing decision-making performance in pedestrians who are elderly, visually impaired or blind.

21 Sep 2012

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012

Systems biologist to pursue research into next-generation genome sequencing technology

Systems biologist Edward Marcotte has received a $2.5 million grant from the National Institutes of Health to pursue cutting-edge research in the area of genome sequencing technology.

21 Sep 2012

Researchers use nanoparticles to deliver drugs to mitochondria within cells

Nanoparticles have shown great promise in the targeted delivery of drugs to cells, but researchers at the University of Georgia have refined the drug delivery process further by using nanoparticles to deliver drugs to a specific organelle within cells.

21 Sep 2012

First Edition: September 20, 2012

Today's headlines include reports that the health law's penalty for not obtaining health insurance could hit as many as 6 million people.

21 Sep 2012

Titan Spine receives U.S. patent for competitive interbody devices

Titan Spine, a medical device surface technology company focused on the development of innovative spinal interbody fusion implants, announced today that it has been awarded patent #US 8,262,737 B2 by the United States Patent Office that protects the Company against competitive interbody devices with a roughened surface topography, anti-expulsion edges, and access to a hollow center.

21 Sep 2012

FDA data collection and analysis about arsenic levels in rice

As part of an ongoing and proactive effort to monitor food safety and address contaminants in food, the U.S. Food and Drug Administration today released preliminary data on arsenic levels in certain rice and rice products. The data are part of a larger FDA data collection and analysis about arsenic levels in rice and is based on the first set of approximately 200 samples of rice and rice products collected in the U.S. marketplace.

21 Sep 2012

Sagard Capital acquires IntegraMed

Sagard Capital Partners, L.P. and IntegraMed America, Inc., a leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, today announced the completion of Sagard Capital's acquisition of IntegraMed for $14.05 per share in cash, representing a total equity purchase price of approximately $169.5 million.

21 Sep 2012

MiR-34a plays a key role in obesity

Scientists have identified a key molecular player in a chain of events in the body that can lead to fatty liver disease, Type II diabetes and other metabolic abnormalities associated with obesity. By blocking this molecule, the researchers were able to reverse some of the pathology it caused in obese mice.

21 Sep 2012

TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

Sanofi and the Global Alliance for TB Drug Development announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide in 2010.

21 Sep 2012

Study finds nearly 50% decline in child mortality in Niger over the last decade

A study by researchers at the Johns Hopkins Bloomberg School of Public Health and the Niger Countdown Case Study Working Group found that child mortality in Niger-one of the world's poorest countries-declined nearly 50 percent over the last decade.

21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Cytochroma today announced the initiation of a phase 3 study of CTAP101 capsules in patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

21 Sep 2012

Viewpoints: Romney's comments point to entitlements' role as big part of 'budget paralysis;' Kristof says candidate inflated 'underlying truth'

Stigmatizing almost everyone with a federal benefit is not just bad politics. It's the worst sort of social stereotyping. But beyond (GOP presidential candidate Mitt) Romney's bluster lies a genuine problem.

21 Sep 2012

Medical News

St. Jude Medical’s Eon family of neurostimulators receives European CE Mark approval

Newly formed emotional memories can be erased from the human brain

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Research to gauge effectiveness of street-crossing training program in impaired people

Hypertonic solution effective in reducing inflammation

Systems biologist to pursue research into next-generation genome sequencing technology

Researchers use nanoparticles to deliver drugs to mitochondria within cells

First Edition: September 20, 2012

Titan Spine receives U.S. patent for competitive interbody devices

FDA data collection and analysis about arsenic levels in rice

Sagard Capital acquires IntegraMed

MiR-34a plays a key role in obesity

TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

Study finds nearly 50% decline in child mortality in Niger over the last decade

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Cytochroma commences CTAP101 phase 3 study in secondary hyperparathyroidism

Viewpoints: Romney's comments point to entitlements' role as big part of 'budget paralysis;' Kristof says candidate inflated 'underlying truth'

High uric acid precursor of obesity, metabolic syndrome

Benefits limited of surgery weight loss for sleep apnea

Sweet success healing diabetic foot ulcers

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News